Akoya Biosciences, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash interest expense
Stock-based compensation expense
Deferred taxes
Change in fair value of contingent consideration
Credit losses on accounts receivable
Net accretion of marketable securities
Change in fair value of warrant liability
Loss on sale of property and equipment
Loss (gain) on extinguishment of debt
Operating lease right of use assets
Provision for excess and obsolete inventories
Impairment
Changes in operating assets and liabilities:
Accounts receivable, net
Prepaid expenses and other assets
Inventories, net
Accounts payable
Accrued expenses and other liabilities
Operating lease liabilities
Deferred revenue

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchase of marketable securities
Sales of marketable securities
Maturities of marketable securities
Net cash (used in) provided by investing activities
Financing activities
Proceeds from initial public offering, net of underwriting discounts and commissions
Sale of common stock in underwritten offering, net of costs
Proceeds from stock option exercises
Settlement of restricted stock units for tax withholding obligations
Principal payments on financing leases
Proceeds from debt
Payment of accrued final fee
Payments of debt issuance costs
Principal payments on capital leases
Payments of deferred offering costs
Payments of contingent consideration
Net cash (used in) provided by financing activities

Net (decrease) increase in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of year
Cash, cash equivalents, and restricted cash at end of year
Supplemental disclosures of cash flow information
Cash paid for interest
Cash paid for income taxes
Supplemental disclosures of non-cash activities
Right-of-use asset obtained in exchange for lease liabilities
Unpaid offering costs related to sale of common stock in underwritten offering
Purchases of property and equipment included in accounts payable and accrued expenses
Accretion of dividends on Series B, C, and D Preferred Stock
Conversion of convertible preferred stock into common stock upon completion of initial public offering
Reclassification of warrant liability to equity

Comments